• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 28, 2017

View Archived Issues

Bench Press: BioWorld looks at translational medicine

Researchers from Emory University have identified microbiome-produced metabolites that extended healthspan in aged flies, worms, and mice, without affecting lifespan. Much of anti-aging research has been focused on lifespan extension, but in many cases, extending lifespan in animals has not extended their healthspan, meaning that the net result of lifespan extension is that they have spent more time frail or sick. Read More

In the clinic

Blake Insomnia Therapeutics Inc., of New York, submitted a clinical trial application to Health Canada seeking permission to start phase II testing of its third-generation beta blocker Zleepax (ZLX-1). Read More

Appointments and advancements

Swedish Orphan Biovitrum AB, of Stockholm, named Trista Morrison vice president of communications for North America. Read More

Other news to note

Vanc Pharmaceuticals Inc., of Vancouver, British Colombia, received Health Canada Class-III approval for Hema-Fer. The updated dosing recommendations now state that Hema-Fer is safe to use in pregnancy to prevent iron deficiency and iron deficiency anemia. Read More

IBS market starts to heat up; still plenty of patients to treat

Prescriptions for Ironwood Pharmaceuticals Inc. and Allergan plc’s Linzess (linaclotide) have been written for 1.5 million unique patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) since the drug was launched at the end of 2012. Read More

Going ‘little’ to go big, Parvus uses nano approach to tamp down autoimmune disease

Efforts to stem the global tide of type 2 diabetes and its unrelenting sequelae have grabbed the lion’s share of attention, and money, for drug development in the space. Read More

Novartis picks up rights to Xoma anti-IL-1 beta assets for $31M, plus debt payment

Xoma Corp. is licensing to Novartis AG global commercial rights to its interleukin-1 (IL-1) beta antibody gevokizumab in the wake of Les Laboratories Servier’s decision last year to quit the asset. Read More

Take-LID-off time re price of Gocovri to come shortly; Adamas label in PD strong

Adamas Pharmaceuticals Inc.’s chief medical officer (CMO) Rajiv Patni told BioWorld that a full development program “just like one would do for a new chemical entity [NCE]” gets credit for the strong label – touting efficacy even during patients’ “off” times – for Gocovri (amantadine extended-release capsules), cleared by the FDA last week for levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD). Read More

New 'Dimension' expands gene therapy pipeline for Regenxbio

Given the implied value of just $3.41 per share (NASDAQ:DMTX) for the all-stock acquisition of Dimension Therapeutics Inc., Evercore ISI analyst Josh Schimmer asked Kenneth Mills, president and CEO of acquirer Regenxbio Inc., the question that likely was on everyone’s mind during a conference call to discuss the transaction. Could another suitor emerge with a competing bid? Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe